Anticoagulation under-utilization in atrial fibrillation patients is responsible for a large proportion of strokes

Banafsheh Shakibajahromi1, Scott E Kasner1, Catherine Schmitt1

  • 1University of Pennsylvania, Department of Neurology.

Insights

Underutilization of anticoagulation (AC) in atrial fibrillation (AF) patients significantly increases the risk of stroke requiring endovascular thrombectomy (EVT). Most AF strokes needing EVT are potentially preventable with adequate AC therapy.

Area of Science:

  • Neurology
  • Cardiology
  • Public Health

Background:

  • Atrial fibrillation (AF) is a major cause of large strokes, often necessitating endovascular thrombectomy (EVT).
  • Underutilization of anticoagulation (AC) therapy is a frequent reason for AF-related strokes.
  • Identifying preventable strokes is crucial for improving patient outcomes.

Purpose of the Study:

  • To compare antithrombotic medication use in AF patients who did and did not undergo EVT.
  • To determine if AC underutilization disproportionately leads to strokes requiring EVT.
  • To quantify the number of EVTs that could potentially be prevented by adequate AC.

Main Methods:

  • Retrospective cohort study of acute ischemic stroke patients (2016-2021).
  • Patients categorized by AF presence and EVT status.
  • Comparison of pre-admission antithrombotic medications and reasons for AC non-use.

Main Results:

  • Of 644 AF patients, 213 underwent EVT.
  • EVT patients were more likely to be off antithrombotics (34% vs 24%) or sub-therapeutically anticoagulated (83% vs 63% on warfarin).
  • Only 44% of AF-EVT patients were on AC, with 31% adequately anticoagulated; only 8% had contraindications, and 94% were discharged on AC.

Conclusions:

  • Lack of antithrombotic therapy in AF patients disproportionately contributes to strokes requiring EVT.
  • A small minority of AF patients have contraindications to AC.
  • Adequate anticoagulation can prevent a significant number of strokes requiring EVT.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
16
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
824
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
582
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
24